雄激素受体剪切变异体阳性去势抵抗性前列腺癌新型药物  

New drugs for androgen receptor splice variant positive castration-resistant prostate cancer

作　　者：罗帆 柳建军 张国辉 梁凯轩 叶裕荣 罗皓文 叶木石 LUO Fan;LIU Jian-jun;ZHANG Guo-hui;LIANG Kai-xuan;YE Yu-rong;LUO Hao-wen;YE Mu-shi(Department of Urology,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)

机构地区：[1]广东医科大学附属医院泌尿外科,广东湛江524000

出　　处：《广东医科大学学报》2023年第1期101-105,共5页Journal of Guangdong Medical University

摘　　要：雄激素受体剪切变异体(AR-Vs)被认为是去势抵抗性前列腺癌(CRPC)发展的重要机制,也是AR靶向药物耐药的关键因素。目前AR-Vs靶向药物明显提高了CRPC患者生存率、改善了生活质量。该文综述了AR-Vs阳性CRPC的新型药物。Androgen receptor splice variants(AR-Vs) are considered to be important mechanisms for the development of castration-resistant prostate cancer(CRPC), and key factors for AR-targeted drug resistance. Currently AR-Vs targeted drugs can improve the survival rate and quality of life of CRPC patients. This article reviews the novel drugs for AR-Vs positive CRPC.

关 键 词：雄激素受体 剪切变异体 前列腺癌 

分 类 号：R697[医药卫生—泌尿科学]